Daiichi Sankyo gets FDA nod for Turalio
Daiichi Sankyo’s Turalio is the first and only approved therapy for adult patients with symptomatic tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to improvement with surgery, the company said.